BDX Options Turn Bullish as Short Sellers Retreat Before Thursday's Print

Becton, Dickinson and Company reports fiscal fourth-quarter results on November 5, and the most striking feature of the current setup is not what bears are doing but what they have stopped doing.

Short interest has fallen nearly 9% over the past month to 2.9% of the free float, a level that puts BDX firmly in the low-conviction camp for short sellers. The lending market confirms the picture: availability is extraordinarily loose at 2,485%, meaning roughly 25 shares remain available to borrow for every one currently lent out. Borrowing costs have drifted lower too, down 14% over the past week to just 0.40%. Nothing in the borrow market suggests meaningful pressure on the stock from the short side heading into Thursday.

Options positioning has swung in the opposite direction. The put/call ratio is running at 0.36, nearly a full standard deviation below its 20-day average of 0.44, and well off the 0.93 peak reached earlier in the year. That marks a clear shift toward calls, with traders paying up for upside exposure rather than hedging. The move is notable because the PCR was consistently above 0.52 throughout September and into early October before dropping sharply around mid-October, the same period when the stock began its 8.7% monthly recovery to $197.88. BDX is only down 0.5% over the past week, a better outcome than the median decline of roughly 1.7% across its closest correlated peers, including STE and ZBH, both of which fell more than 2%.

The analyst community is cautiously constructive but hardly unanimous. The consensus sits at Buy, though the mean price target of $196 is barely below where the stock is trading, leaving little implied upside. Barclays initiated coverage in early October with an Underweight rating and a $165 target, the most bearish recent voice on the street. B of A Securities, maintaining Neutral, raised its target to $200 in late August. The tension between those two poles reflects the genuine strategic uncertainty around BDX post-separation. The bull case rests on the company becoming a cleaner, pure-play MedTech platform following the Biosciences and Diagnostics spin-off, with buybacks as the primary use of the roughly $4 billion cash distribution and adjusted operating margin holding near 25%. The bear case centres on a fragile post-separation structure: Alaris is expected to be a roughly 100 basis point headwind in fiscal 2026 and around 200 basis points in fiscal 2027, China remains a risk despite representing only 4% of new BD revenue, and management's own downside scenario implies weaker revenue growth with margin pressure from tariffs and business investment.

Institutional ownership offers one data point worth noting. The Vanguard Group's 13D/G register shows a significant shift: its filing from March 2026 shows a stake that went from 12.85% to effectively zero, while two separate Vanguard entities filed new 13G disclosures in April 2026 for 7.51% and 5.4% stakes respectively. This appears to reflect the restructuring of Vanguard's reporting entities following the BD separation rather than a genuine exit, though stakes are disclosed as of last filing around the 5% threshold and positions can change without a subsequent filing. First Eagle Investment Management also crossed the 5% threshold and filed a new 13G in August 2026 with a 5.1% stake.

The print on Thursday tests whether BD's first full-quarter results as a refocused MedTech platform can meet the earnings momentum implied by factor scores ranking in the 88th and 89th percentile for EPS momentum over the past 30 and 360 days respectively, against a market now positioned more for upside than downside protection.